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Abstract
Background: Neurotoxicity is a common side effect of treatment with calcineurin inhibitors. Tremors are frequently
reported as the most common manifestation. Variable presentations can include headaches, seizures, visual
hallucinations or blindness. Sixth nerve palsy has been reported in previous cases of bone marrow and cardiac
transplant patients receiving calcineurin inhibitors. In many of these previously reported cases, the drug was
administered intravenously and very high drug levels were found.
Case presentation: We report the first case of isolated diplopia in a patient being treated for idiopathic
membranous glomerulonephritis. This is also the first report where the neurotoxicity induced by initial tacrolimus
therapy persisted with subsequent cyclosporine therapy, two structurally different calcineurin inhibitors which share
a common mechanism of action. In our case toxicity occurred after 3 months of therapy despite low serum
concentrations and the symptoms resolved completely after discontinuation of the drugs.
Conclusion: Our case provides further evidence that the neurotoxicity is a result of calcineurin inhibition.
Monitoring of serum concentrations of these drugs has not been correlated with toxicity. The mean duration to
onset of symptoms can be as much as 70 days suggesting accumulation of the drug in the central nervous system
plays a role. Recognition of this condition is important for prompt diagnosis and appropriate management.
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Background
Calcineurin inhibitors cyclosporine (CyA) and tacroli-
mus (FK506) are widely used immunosuppressive drugs
used to treat transplant recipients, autoimmune diseases
and nephrotic syndrome. CyA and FK506 bind to cyclo-
philin and FK binding protein respectively and the resulting
complex inhibits calcineurin. Besides lymphocytes, calcine-
urin is also found in abundance in the nervous tissues.
These drugs are lipophilic and move across the blood brain
barrier easily. Diverse neurotoxicities ranging from tremors
(most common, up to 40 %), headache, altered mental
status, hallucinations, psychosis, peripheral neuropathy,
seizures, cerebellar ataxia and leukoencephalopathy have
been reported in the literature. In most cases the calcine-
urin therapy induced neurotoxicity is reversible after
withdrawal of the medication. We report for the first time a
case of isolated diplopia in a patient with idiopathic
membranous nephropathy on treatment with calcineurin
inhibitors.
Case presentation
Our case is a previously healthy 42 year-old Caucasian
female with biopsy proven idiopathic membranous
nephropathy (MGN) who was being treated with FK506
and prednisone for nephrotic syndrome. She was a never
smoker and did not have a prior history of hypertension
or diabetes. She tested negative for ANA, ANCA vascu-
litis, HIV, hepatitis B and C. Her kidney biopsy showed
typical features of membranous glomerulonephritis in
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addition to positive staining with the anti-phospholiapse
A2 receptor antibody which identifies idiopathic MGN
with 97 % specificity [1]. Serum Tacrolimus levels were
maintained between 6 and 8 ng/mL. She responded
favorably to treatment and her initial urine protein/cre-
atinine ratio of 8 gm/gm declined to less than 1 gm/gm
within the initial 2 weeks of therapy. Her serum albumin
level of 2 gm/dL prior to initiation of therapy improved
to 3.3 gm/dL after 3 weeks of initiation of treatment
(Fig. 1). The patient also developed hypertension as a
side effect of calcineurin inhibitor therapy and was
treated with Losartan 100 mg PO daily. Her blood
pressure remained well controlled throughout the treat-
ment period and hypertension resolved once therapy
was discontinued. After 3 months of therapy she
presented with diplopia. She was in complete remission
at this time and her serum albumin had normalized to
4 gm/dL. Her clinical course is depicted in Fig. 1. The
diplopia was gradual in onset, binocular and vertical and
more prominent in the later part of the day. The patient
was seen for an ophthalmologic evaluation. Her visual
acuity was 20/20. Pupils were equal and reactive to light
and accommodation. No nystagmus or ptosis was
observed. Visual fields and color vision was also normal
in both eyes. Assay for acetylcholine receptor antibody
done to rule out myasthenia gravis was negative. A CT
scan of the brain done to rule out an infarct was normal.
The diplopia persisted for over 4 weeks while the patient
remained compliant with her medications despite the
side effects. The symptoms persisted even when her
tacrolimus dose was reduced and repeat levels were
between 4 and 5 ng/mL. 3 weeks after onset of diplopia
she was switched to low dose CyA in anticipation that
similar side effects may not be observed. Trough CyA
levels were 44 ng/mL and 59 ng/mL on two occasions
but her symptoms did not resolve. A consultation with
neuro-ophthalmology was sought and the patient was
instructed to discontinue CyA. The symptoms completely
resolved 6 days after stopping CyA. Her nephrotic
syndrome remains in remission till date.
Conclusion
A review of the literature found 6 cases of eye movement
disorders in association with calcineurin inhibitor therapy.
The relevant clinical findings of these are summarized in
Table 1. All of these occurred in patients with solid organ
[2] or bone marrow transplants [3, 4] and were associated
with high levels of CNIs. Our case is unusual in several
respects. This is the first reported case in a patient with
nephrotic syndrome. Also, this is the first reported case
where manifestations persisted even when the patient was
switched from FK506 to low dose CyA. CyA and FK506
are structurally different but share a common mechanism
of action. Openshaw et al. [4] postulated that eye
movement disorders in bone marrow transplant patients
could be a result of combined treatment with CyA and
ganciclovir. Our case reinforces the belief that neurotoxicity
is mediated through calcineurin inhibition. In the setting of
profound hypoalbuminemia like seen in our patient early in
the course of disease, whole blood concentration of tacroli-
mus have a very variable relationship to the unbound
fraction of the drug. In general, aiming for the same whole
blood concentration can vastly underestimate the unbound
fraction thereby leading to toxicity [5]. In our patient the
Fig. 1 Patient's clinical course
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diplopia developed after serum albumin had normalized.
However, the preceding hypoalbuminemia may have
led to greater accumulation of the drug in the central
nervous system, thereby predisposing the patient to
toxicity. This case highlights the variable and unpre-
dictable nature of calcineurin inhibitor neurotoxicity.
A predictable correlation between drug levels and
neurotoxicity has not been found previously, but it
may be related to total amount of drug and its accu-
mulation within the central nervous system. In all
previously reported cases the average time to onset
was 74 days is similar to our case. A hyper intense
T2 weighted MRI lesion in the occipital lobe (revers-
ible posterior cerebral edema syndrome) is commonly
reported as an indicator of neurotoxicity. Similar MRI
findings can also be seen in hypertensive encephalop-
athy caused by vasospasm, loss of auto regulation and
local edema. Diplopia can also be caused cranial
nerve III, IV or VI palsy or vascular phenomenon
such as vasospasm or an ischemic infarct. Our patient
did not have any risk factors for microvascular dis-
ease including diabetes, hypertension or smoking. Our
patient had well controlled blood pressures through-
out treatment and a CT of the brain was reported
normal. Therefore the patient’s symptoms cannot be
attributed to a vascular phenomenon. Binocular diplo-
pia which is only present with both eyes open ex-
cludes disorders of the ocular media such as cataracts
or astigmatism. Our patient underwent a complete
ophthalmologic evaluation which was normal. Further,
prolonged duration of symptoms and the temporal
correlation between discontinuation of the drug and
resolution of symptoms strengthens our belief that
this was a result of drug toxicity.
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